| Literature DB >> 26491454 |
Keneuoe Hycianth Thinyane1, Keanole Mofona Motsemme1, Varsay Jim Lahai Cooper2.
Abstract
Meningitis causes significant morbidity and mortality globally. The aim of this study was to study the clinical presentation, aetiology, and outcomes of meningitis among adult patients admitted to Queen Mamohato Memorial Hospital in Maseru, Lesotho, with a diagnosis of meningitis. A cross-sectional study was conducted between February and April 2014; data collected included presenting signs and symptoms, laboratory results, and clinical outcomes. Descriptive statistics were used to summarise data; association between variables was analysed using Fisher's exact test. 56 patients were enrolled; the HIV coinfection rate was 79%. The most common presenting symptoms were altered mental status, neck stiffness, headache, and fever. TB meningitis was the most frequent diagnosis (39%), followed by bacterial (27%), viral (18%), and cryptococcal meningitis (16%). In-hospital mortality was 43% with case fatalities of 23%, 40%, 44%, and 90% for TB, bacterial, cryptococcal, and viral meningitis, respectively. Severe renal impairment was significantly associated with mortality. In conclusion, the causes of meningitis in this study reflect the high prevalence of HIV and TB in our setting. Strategies to reduce morbidity and mortality due to meningitis should include improving diagnostic services to facilitate early detection and treatment of meningitis and timely initiation of antiretroviral therapy in HIV-infected patients.Entities:
Year: 2015 PMID: 26491454 PMCID: PMC4605366 DOI: 10.1155/2015/423161
Source DB: PubMed Journal: J Trop Med ISSN: 1687-9686
Demographic and baseline characteristics of the study participants.
| Variable |
|
|---|---|
| Female gender, | 32 (57) |
| Age group, years, | |
| 18–24 | 8 (14) |
| 25–34 | 20 (36) |
| 35–49 | 22 (39) |
| >49 | 6 (11) |
| HIV status, | |
| Positive | 44 (79) |
| Negative | 7 (13) |
| Unknown | 5 (9) |
| % on antiretroviral therapy, | 26 (59) |
| Clinical presentation, | |
| Altered mental status | 42 (75) |
| Neck stiffness | 38 (68) |
| Headache | 30 (54) |
| Fever | 24 (43) |
| Seizures | 4 (7) |
| Baseline biochemistry, median (IQR) | |
| CD4 count, cells/mm3, | 100 (53–155) |
| Na+, mmol/L, | 131.0 (128.0–137.3) |
| K+, mmol/L, | 4.0 (3.4–4.9) |
| eGFR, mL/min, | 57 (26–78) |
| ALT, U/L, | 39 (27–77) |
| Hb, g/dL, | 11.0 (9.0–13.0) |
| PLT, ×103/L, | 273 (186–336) |
Data presented as n (%) unless otherwise stated; ALT: alanine transaminase; Hb: haemoglobin; n: number of patients; N: total number of patients for whom the analysis was performed; PLT: platelets.
Cerebrospinal fluid analysis and clinical outcomes.
| BM | CM | TBM | VM | |
|---|---|---|---|---|
| ( | ( | ( | ( | |
| HIV positive, | 11/13 (85) | 8/9 (89) | 15/19 (79) | 10/10 (100) |
| % on ARTb | 8/11 (73) | 3/8 (38) | 11/15 (73) | 4/10 (40) |
| CD4 count, median, cells/mm3 (IQR) | 162 (91–257) | 18 (12–41) | 119 (100–277) | 102 (75–129) |
|
| ||||
| CSF analysis | ||||
| Gram stain (+) | 12c/15 (80) | 0 (0) | 0 (0) | 0 (0) |
| Bacterial antigen test (+) | 4c/15 (27) | 0 (0) | 0 (0) | 0 (0) |
| India ink (+) | 0 (0) | 6/9 (67) | 0 (0) | 0 (0) |
| CSF CRAG (+) | 0 (0) | 8/9 (89) | 0 (0) | 0 (0) |
| White blood cells | ||||
| Range, cells/mm3 | 0–420 | 0–184 | 8–2393 | 0–18 |
| Median, cells/mm3 (IQR) | 7 (2–147) | 10 (0–86) | 217 (58–435) | 0 (0-0) |
| >5 cells/mm3, | 9/15 (60) | 5/9 (56) | 22/22 (100) | 2/10 (20) |
| Lymphocytic pleocytosisd | 2/9 (22) | 4/5 (80) | 20/22 (91) | 2/2 (100) |
| Glucose | ||||
| Median, mmol/L (IQR) | 3.0 (1.1–3.8) | 2.0 (1.0–2.9) | 1.1 (0.6–2.3) | 3.0 (2.7–3.6) |
| <2.2 mmol/L, | 5/15 (33) | 5/9 (56) | 14/22 (64) | 1/10 (10) |
| Protein | ||||
| Median, g/L (IQR) | 0.6 (0.4–1.5) | 1.0 (0.7–1.8) | 2.0 (1.7–4.4) | 0.5 (0.4–0.7) |
| >0.45 g/L, | 11/15 (73) | 8/9 (89) | 20/22 (91) | 7/10 (70) |
|
| ||||
| Hospital stay, median days (IQR) | 11 (9–12) | 17 (17–23) | 11 (8–11) | 23 (23-23) |
| Mortality rate, | 6/24 (25) | 4/24 (17) | 5/24 (21) | 9/24 (38) |
| Fatality rate, | 6/15 (40) | 4/9 (44) | 5/22 (23) | 9/10 (90) |
aHIV infection rate expressed as a percentage of patients with known HIV status; bexpressed as a percentage of patients with HIV infection; cpositive Gram stain and bacterial antigen results reported for initial and repeat CSF specimens; dcalculated as a percentage of patients with CSF white cells >5 cells/mm3; BM: bacterial meningitis; CM: cryptococcal meningitis; MN: mononuclear cells; n: number of patients; N: total number of patients for whom the analysis was performed; PMN: polymorphonuclear cells; TBM: tuberculous meningitis; VM: viral meningitis.
Analysis of factors associated with in-hospital mortality.
| Survived | Died |
| |
|---|---|---|---|
| Age, years | |||
| >49 | 2 | 4 | 0.385 |
| ≤49 | 30 | 20 | |
| Gender | |||
| Male | 14 | 10 | 1.000 |
| Female | 18 | 14 | |
| HIV status | |||
| Positive | 23 | 21 | 0.436 |
| Negative | 5 | 2 | |
| CD4 count, cells/mm3 | |||
| <100 | 7 | 7 | 0.715 |
| ≥100 | 9 | 6 | |
| Altered mental status | |||
| Yes | 21 | 21 | 0.072 |
| No | 11 | 3 | |
| Seizures | |||
| Yes | 3 | 1 | 0.627 |
| No | 29 | 23 | |
| Serum sodium, mmol/L | |||
| <130 | 11 | 5 | 0.750 |
| ≥130 | 18 | 12 | |
| eGFR, mL/min | |||
| <30 | 2 | 8 | 0.008 |
| ≥30 | 26 | 10 |